SHR-2106

N/A

Report date: 2025/02/25 11:17:53

Base Information

Drug NameSHR-2106
Drug Alias NameSHR-2106SHR2106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationSjogren's Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangdong Hengrui Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangdong Hengrui Pharmaceutical Co LtdSuzhou Suncadia Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsRejection of organ transplantationRejection of renal transplantationSjogren's Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A